Literature DB >> 9873793

Factor VIII immunogenicity.

M G Jacquemin, J M Saint-Remy.   

Abstract

The immunogenicity of factor VIII depends on the interaction of multiple parametres including host susceptibility and characteristics of the factor VIII preparations. We briefly review here the basic mechanisms by which tolerance to self is established, maintained, and possibly broken in the context of haemophilia A, with special emphasis on the severity of the disease. Reference is also made to the situation observed in healthy individuals and patients with autoantibodies to factor VIII.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9873793     DOI: 10.1046/j.1365-2516.1998.440552.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

1.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

2.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

3.  Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.

Authors:  Matthew P Kosloski; Aaron Peng; Prashant R Varma; Anas M Fathallah; Razvan D Miclea; Donald E Mager; Sathy V Balu-iyer
Journal:  Drug Deliv       Date:  2010-11-30       Impact factor: 6.419

4.  Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.

Authors:  Aaron Peng; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2010-06-02       Impact factor: 4.009

5.  Phospholipid binding lowers immunogenicity of human recombinant factor VIII in von Willebrand factor knockout mice.

Authors:  D S Pisal; S V Balu-Iyer
Journal:  Thromb Haemost       Date:  2011-04-07       Impact factor: 5.249

6.  Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.

Authors:  Krithika A Shetty; Elizabeth P Merricks; Robin Raymer; Natalie Rigsbee; Timothy C Nichols; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2016-06-30       Impact factor: 3.534

7.  Development and characterization of lipidic cochleate containing recombinant factor VIII.

Authors:  Razvan D Miclea; Prashant R Varma; Aaron Peng; Sathy V Balu-Iyer
Journal:  Biochim Biophys Acta       Date:  2007-08-19

Review 8.  Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.

Authors:  Anshu Kuriakose; Narendra Chirmule; Pradip Nair
Journal:  J Immunol Res       Date:  2016-06-29       Impact factor: 4.818

Review 9.  Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Nicole L Jarvi; Sathy V Balu-Iyer
Journal:  BioDrugs       Date:  2021-02-01       Impact factor: 5.807

10.  Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.

Authors:  Zuben E Sauna; Chinyere Okunji; Ryan C Hunt; Tanvi Gupta; Courtni E Allen; Elizabeth Plum; Adam Blaisdell; Vahan Grigoryan; S Geetha; Robert Fathke; Kenji Soejima; Chava Kimchi-Sarfaty
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.